OBJECTIVES: Irrational drug use is a limitation to diabetes management. It leads to medication non-adherence, drug therapy problems, treatment failure, complications and avoidable deaths. This study analyzed the utilization pattern of anti diabetes drugs in the outpatient clinic to document information for promoting the rational use of drugs in type 2 diabetes. METHODS: The study was a retrospective observational study of ambulatory students who visited the hospital for type 2 diabetes mellitus (T2DM) care. Patients’ medical records were assessed retrospectively and analyzed for drug utilization. Patients who have visited the hospital for more than 12 months were used for the study which lasted for ten months. All the medical records of type 2 diabetes patients which met the inclusion criteria were used for the study. The result was analyzed using descriptive statistics. RESULTS: The study utilized 285 medical records which comprised of 121.0 (42.5%) males and 164.0 (57.5%) females. The number of patients <40 years was 11.0 (3.9%) while the modal age range of 651- 70 years was 86.0 (30.1%). While 199.0 (70.0%) have lived with T2DM for more than 10 years. The most prescribed drugs were endocrine drugs 467.0 (21.7%), cardiovascular drugs 592.0 (27.6%), analgesics 249.0 (11.6%), and anti-infective 231.0 (10.8%). Metformin 208.0 (43.5%) was the most prescribed anti-diabetes drug, followed by glibenclamide 114.0 (23.8%) and glimepiride 66.0 (13.8%). The anti hypertensive most prescribed was hydrochlorothiazide 166.0 (23%), followed by frusemide 135.0 (18.9), and lisinopril 127.0 (17.8%). The antidiabetes combinations used were metformin+glibenclamide 71.0 (48.6%), and metformin+glimepiride 42.0 (28.8%). The triple combinations used were metformin+glibenclamide+pioglitazone 21.0 (14.4%), and metformine+glimepiride+pioglitazone (12.0 (8.2). CONCLUSIONS: Metformine was the most prescribed antidiabetes monotherapy while metformin+glibenclamide was the highest double combination and metformin+glibenclamide+pioglitazone was the most prescribed triple combination. These suggest some level of tolerability among patients, and compatibility among the combined therapeutic agents.